Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy
and in combination with Sym021 in patients with solid tumor malignancies.